Another Call for Better Risk Stratification in Cardiac Imaging
This article was originally published in Start Up
New data showing that the slightly more than one-third of patients with previously unconfirmed coronary artery disease who go to the cath lab for invasive angiography testing actually have an obstructive blockage are sure to ratchet up the already active discussions around the appropriate use of cardiac imaging - both from the effectiveness and safety perspectives. Part of the solution may be the development of molecular IVD tests aimed at triaging patients to imaging. Even if slow to integrate this brand of R&D into their development strategies, some makers of in vivo imaging equipment are beginning to realize this.
You may also be interested in...
GE Acquires Clarient To Anchor Its Molecular IVD Business
GE is buying Clarient, which provides molecular cancer tests. It intends to make Clarient the cornerstone around which it builds out a molecular in vitro diagnostics business, combining Clarient with its own diagnostic imaging expertise to give it a full suite of triage and cancer diagnostic capabilities. In some ways, it could solve GE's long-standing issue of how to innovate in healthcare and move into high-value businesses without taking on the risks and timelines of pharma-style R&D.
Radiation Safety Concerns Could Drive New Legislation, Quality Standards
Before it decides on a legislative approach to address medical radiation safety, the Health Subcommittee of the House Energy and Commerce Committee will likely delve into the topic further, Subcommittee Chairman Frank Pallone, Jr., D-N.J., said during a Feb. 26 hearing
CardioDx: Bringing Molecular Diagnostics Into the Cardiovascular Arena
Buoyed by their success with Genomic Health, a trio of West Coast VCs have expanded their portfolios of molecular diagnostic companies, with many following similar themes. CardioDx has developed a test to distinguish between patients who should move on to cardiac imaging and those they are comfortable managing otherwise. Such a rule-out test is a challenging proposition. But if adopted, and more broadly, as molecular diagnostics move into new and broad markets like cardiology and metabolic disease, pharma could use this opportunity to its advantage in many settings, including co-marketing arrangements.